New Delhi, Nov 14 (PTI) Ipca Laboratories on Thursday said its consolidated net profit declined 58 per cent year-on-year to Rs 229 crore in the September quarter.

The drug firm had reported a net profit of Rs 145 crore in the year-ago period.

Also Read | World Diabetes Day 2024 Theme: What Are Symptoms of Diabetes? How To Prevent Diabetes? Know About Government of India’s Diabetes Prevention Initiatives.

Revenue from operations rose to Rs 2,355 crore for the second quarter of the current fiscal year as compared with Rs 2,034 crore in the year-ago period, Ipca Laboratories said in a regulatory filing.

The company said its domestic formulations business revenue stood at Rs 940 crore for the quarter, up 11 per cent from Rs 845 crore a year earlier.

Also Read | Janjatiya Gaurav Divas 2024: Celebrating Tribal Heritage on Bhagwan Birsa Munda Jayanti.

Export of generics stood at Rs 286 crore in the July-September period as against Rs 264 crore, registering a year-on-year growth of 8 per cent.

The company said its board has approved an interim dividend of Rs 21 per share of Re 1 each for 2024-25.

Shares of the company on Thursday ended 2.02 per cent up at Rs 1,538.65 apiece on the BSE.

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)